We review the role of upfront FLT3 inhibitors and specifically highlight the ongoing efforts to develop more effective frontline therapies for older adults with FLT3-mutated AML who are unfit for intensive chemotherapy, including novel triplet regimens that integrate FLT3 inhibitors into lower-intensity backbones. This evidence concerns the gene FLT3 and acute myeloid leukemia.